InCarda Therapeutics, which is developing an inhaled treatment for paroxysmal atrial fibrillation, has appointed former Gilead Senior VP for Cardiovascular Therapeutics Luiz Belardinelli as Chief Medical Officer, the company said. Belardinelli will continue as a Senior Advisor for Gilead while working for InCarda half time.
In April 2015, InCarda announced that it had raised $5 million for development of inhaled cardiotherapeutics, and in December of that year, the US-based company announced that it was opening an Australian subsidiary in preparation for its first clinical program.
InCarda President and CEO Grace E. Colon said, “We are thrilled to have Dr. Belardinelli join our team. As a recognized global expert in cardiac arrhythmias such as atrial fibrillation we will benefit from his preclinical and clinical knowledge and regulatory experience—both in the US and abroad—as well as his vast network of colleagues in this space. Dr. Belardinelli joins us at an important time, as we are on track to initiate a Phase 1 clinical trial in Q2 of this year to evaluate our inhaled formulation of flecainide for treatment of patients with recent onset paroxysmal atrial fibrillation.”
Read the InCarda Therapeutics press release.
